Latest Property Portfolio News

Wide Open Agriculture cut its loss to $3.64 million in FY2026 as it pivots from owning manufacturing to a capital-light contract model, while securing global commercial traction for its lupin-based ingredients.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.

Provaris Energy reported a $4.045 million loss for FY2026 as it progressed proprietary hydrogen and liquid CO₂ storage technologies, expanded strategic partnerships, and boosted cash reserves through multiple placements.

Dexus has delivered a 37.0 cents per security distribution for FY26, matching guidance despite economic headwinds, while initiating a strategic review of infrastructure funds acquired in 2023 and forecasting lower earnings in FY27.

Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.

Harvey Norman Holdings reported a 10.9% rise in profit before tax excluding one-off adjustments, driven by international retail growth and a robust property portfolio. The company declared a fully franked 13 cent final dividend, maintaining a strong balance sheet with conservative gearing.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

CTI Logistics (ASX:CLX) posted a 69% jump in net profit to $24 million for FY26, driven by robust transport volumes, logistics growth and a $74 million uplift in property valuations. The company also declared a 14 cents per share fully franked dividend.

Desane Group Holdings posted a statutory net profit after tax of just $0.02 million for FY26, down sharply from $3.32 million the previous year, while advancing key property developments and maintaining a strong balance sheet.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

K&S Corporation’s FY2026 profit fell 16% underlying, with a 31% dividend cut reflecting cautious outlook amid economic uncertainty and contract losses.

WOTSO Group posted a 4% rise in operating income to $48.75 million for FY2026, cutting its net loss attributable to securityholders by 50% to $2.42 million. Distributions increased to 2.8 cents per stapled security, reflecting cautious progress in its suburban flexible workspace strategy.